CD40 Agonist and PD-1 Inhibitor in HNSCC Head and Neck Squamous Cell Carcinoma 查看 Recruiting Phase 1 University of Pennsylvania 2023-11-16 A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors Malignant Solid Tumo 查看 Recruiting Phase 1 Nozaki Akira 2023-11-07 A Safety ...
CD40 targeted therapies have become a focal point in immunotherapy research, with growing attention on harnessing the potential of the CD40 receptor to treat a variety of diseases. While no CD40 targeted therapies have yet been ap...
Anti-CD40 antibody is often used in combination with other immunology agents in clinical researchs to achieve anti-tumor effects. Here are some published data about CD40 work as a potential target for cancer immunotherapy. A CD40 agonist increases antitumor efficacy of vaccine + anti-PD-1 therapy...
Trial Registration Related to trial #NCT03165994 Reference Ko A NM, Chao J, Sohal DPS. A Multicenter Phase 2 Study of Sotigalimab (CD40 Agonist) in Combination with Neoadjuvant Chemoradiation for Resectable Esophageal and Gastroesophageal Junction (GEJ) Cancers. ESMO Annual Conference. September 9...
Importantly, strong immune memory was established, with an increase in memory CD8 T cells only when both interleukin and the CD40 agonist were combined. Conclusion These novel preclinical data support initiation of a first﹊n﹉uman clinical trial with this combination immunotherapy strategy in ...
(Supplemental Fig2), both the anti-CD40 antibody and Poly I:C contributed to enhanced immune responses, but the impact of the costimulatory antibody was superior to the effects of the TLR agonist. The polyfunctionality of specific CD8+ T cells was investigated in the spleen 34 days after ...
Gliomas are brain tumors characterized by an immunosuppressive microenvironment. Immunostimulatory agonistic CD40 antibodies (αCD40) are in clinical development for solid tumors, but are yet to be evaluated for glioma. Here, we demonstrate that systemic
APX005M has unique structural characteristics compared to other reported CD40 agonist antibodies in clinical development. To determine whether these differences impart distinct functionality of APX005M, we compared the biological activity of analogs of CP-870,893, SGN-40 and ADC-1013. Though all anti...
demonstrated that dual targeting of TAMs with a CD40 agonist and colony stimulating factor 1 (CSF-1) blockade converts TAMs into a pro-inflammatory phenotype. CSF-1 is known to induce generation of myeloid-derived suppressor cells and tolerogenic DCs; therefore, blocking this pathway while ...
In order to build on the first promising results of ICB, there is a clear need to explore additional drugs and treatment regimens in clinical trials. Agonist immunostimulatory antibodies (IS-Abs) targeting activatory receptors on immune cells are a potential alternative for immune checkpoint inhibitor...